Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2016
Reporting Period: First Quarter ended March 31, 2016
This filing serves to announce the Company's financial results for the quarter ended March 31, 2016, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only references the issuance of the Q1 2016 financial results.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release titled "Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results."
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific Q1 2016 revenue, net loss, and cash position figures.
- Verify the "Corporate Update" section in the press release for any changes in clinical trial status or strategic direction.
- Confirm the Company's cash runway and any recent financing activities mentioned in the full press release.
- Check subsequent filings for any updates to the financial data presented in this May 12, 2016 report.